TTOO - T2 Biosystems stock rises after issuance of U.S. patent for direct detection of Lyme disease

T2 Biosystems (NASDAQ:TTOO) on Friday said the U.S. Patent and Trademark Office had issued a patent for methods and systems to rapidly detect tick-borne pathogens, which also covered the company's T2Lyme Panel. TTOO stock +9.7% to $0.23 in morning trade. TTOO said its T2Lyme Panel can identify the bacteria that causes Lyme disease directly from a patient's blood in three to five hours. Lyme disease is caused by the bacteria Borrelia burgdorferi and is transmitted to humans through infected ticks. Typical symptoms include fever, headache, fatigue and skin rash. T2 Biosystems already has FDA-approved detection tests such as its T2Bacteria Panel, which can identify sepsis-causing bacteria, and its T2Candida Panel, which can detect fungal pathogens. The T2Lyme Panel runs on the same instrument as these approved products. TTOO added that currently, there are no FDA-cleared diagnostic tests for the sensitive detection of early Lyme disease.

For further details see:

T2 Biosystems stock rises after issuance of U.S. patent for direct detection of Lyme disease